Dry Age-related Macular Degeneration therapy (Shanghai BDgene)

N/A

Report date: 2025/03/04 14:50:33

Base Information

Drug NameDry Age-related Macular Degeneration therapy (Shanghai BDgene)
Drug Alias NamedAMD (Shanghai BDgene)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsWet age-related macular degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai BDgene Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai BDgene Co Ltd
Inactive CompaniesN/A
Active IndicationsWet age-related macular degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A